跳至主要内容
临床试验/NCT00728650
NCT00728650已完成不适用

A Retrospective Review of Malignant Liver Tumors

University of Oklahoma1 个研究点 分布在 1 个国家目标入组 228 人开始时间: 2003年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
228
试验地点
1
主要终点
Survival

研究概览

简要总结

This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) will be compared with patients not receiving these treatments. Tumor recurrence and survival data will be compared to the published literature to determine the efficacy of current treatment strategies in this patient population.

详细描述

Subjects will be identified by diagnosis and procedure codes from a university surgical practice and the St. John Medical Center Cancer Registry. Data will be obtained by review of both the clinic and hospital charts. In addition we plan to review and utilize liver tumor treatment and outcomes data from a national database. Treatment decisions, in cases managed by the primary investigator, were made on a clinical basis, often in collaboration with an interventional radiologist. Of the patients managed by the principal investigator, all procedures were undertaken after an informed consent process. Subjects were not exposed to risk beyond that posed by the recommended treatment. All treatments were within the scope of standard medical care. The primary investigator has no knowledge of the treatments chosen for the patients he did not manage. The subject's referring physician may be contacted to obtain follow-up data on the subject. The follow-up data will include: is the patient alive with disease; alive without disease, alive unknown; dead free of disease; dead with disease; dead unknown.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with primary or metastatic hepatic malignancies

排除标准

  • Patients not diagnosed with primary or metastatic hepatic malignancies

结局指标

主要结局

Survival

时间窗: lifetime

次要结局

  • Efficacy(lifetime)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验